Clinical pharmacology of selective estrogen receptor modulators (SERMs)

Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs

Volumn , Issue , 2006, Pages 49-69

  Marín, Fernando ^a   Barbancho, Ma Carmen ^b  

^a ELI LILLY AND COMPANY   (United States)

^b HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947591771     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-34742-9_2     Document Type: Chapter

References (76)

1. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C (2001) Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 86:755-760
2. Ammann P, Bourrin S, Bonjour J-P, Brunner F, Meyer J-M, Rizzoli R (1999) The new selective estrogen receptor modulator MDL 103, 323 increases bone mineral density and bone strength in adult ovariectomized rats. Osteoporos Int 10:369-376
3. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al. (1996) Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88:23-25
4. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 287:847-857
5. Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, et al. (2003) Ann Oncol 14:1383-1390
6. Baumann RJ, Bush TL, Cross-Doersen DE, Cashman EA, Wright PS, Zwolshen JH, et al. (1998) Clomiphene analogs with activity in vitro and in vivo against human breast cancer cells. Biochem Pharmacol 55:841-851
7. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, et al. (1994) Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
8. Bourrin S, Ammann P, Bonjour J-P, Rizzoli R (2002) Recovery of proximal tibia bone mineral density and strength but not cancellous bone architecture, after longterm bisphosphonate or selective estrogen receptor modulator in aged rats. Bone 30:195-200
9. Buzdar AU, Hortobagyi GN (1998) Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 26:348-353
10. Buzdar A, Hayes D, El Khoudary A, Yan S, Lonning P, Lichinitser M, et al. (2002) Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/Pg-positive advanced breast cancer. Breast Cancer Res Treat 73:161-175
11. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, et al. (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007-1014
12. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. (2001) Continued breast cancer risk reduction in postmenopausal women treated with Raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125-134
13. Chavassieux P, Garnero P, Duboeuf F, Vergnaud P, Brunner-Ferber F, Delmas PD, et al (2001) Effects of a new selective estrogen receptor modulator (MDL 103, 323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. J Bone Miner Res 16:89-96
14. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L Jr (2000) Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95:104-110
15. Cotreau MM, Stonis L, Dykstra KH, Gandhi T, Gutiérrez M, Xu J, et al. (2002) Multipledose, safety, pharmacokinetics and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. J Clin Pharmacol 42:157-165
16. Díaz Curiel M, Calero JA, Guerrero R, Gala J, Gazapo R, De La Piedra C (1998) Effects of LY-117018 HCl on bone remodeling and mineral density in the oophorectomized rat. Am J Obstet Gynecol 178:320-325
17. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, et al. (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, lacebo-controlled, randomized clinical trial in postmenopausal patients. Can Epidemiol Biomar Prev 10:961-966
18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. J Am Med Assoc 282:637-645.
19. Corrections published in J Am Med Assoc 282:2124
20. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin, et al. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
21. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S (1996) Time dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen and alendronate. Bone 18:621-627
22. Gennari L (2004) Ospemifene. Curr Opin Invest Drugs 5:448-455
23. Goldstein SR, Nanavati N (2002) Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 187:521-527
24. Goldstein SR, Neven P, Zhou L, Taylot YL, Ciaccia AV, Plouffle L (2001) Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 98:91-96
25. Greenbeger LM, Annable T, Collins KI, Komm BS, Lyttle CR, Miller CP, et al. (2001) A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin- 1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydroclorhide (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Clin Cancer Res 7:3166-3177
26. Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C (2002) Comparison of the effects of EM-652(SCH570068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast cancer in nude. Int J Cancer 99:273-278
27. Hendrix SL, McNeeley SG (2001) Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann NY Acad Sci 949:243-250
28. Helvering LM, Adrian MD, Geiser AG, Estrem ST, Wei T, Huang S, et al. (2004) Differential effects of estrogen and raloxifene on mRNA and matrix metalloproteinase 2 (MMP2) activity in the rat uterus. Biol Reprod [Epub ahead of print]. DOI:10.1095/biolreprod.104.034595
29. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 280:605-613
30. Jordan VC, Morrow M (1999) Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253-78
31. Ke HZ, Chen HK, Simmons HA, Crawford DT, Pirie CM, Chidsey-Frink KL et al. (1997) Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20:31-39
32. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons H, et al. (1998) Effects of CP-336, 156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology 139:2068-2076
33. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD (2001) Lasofoxifene (CP-336, 156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res 16:765-773
34. Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD (2000) Lasofoxifene (CP-336, 156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 141:1338-1344
35. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145:1996-2005
36. Komm BS, Lyttle CR (2001) Developing SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 949:317-326
37. Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, et al. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and the endometrium. J Steroid Biochem Mol Biol 69:51-84
38. Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L, et al. (2004) Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol 22:864-871
39. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN (1986) Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 57:40-43
40. Li X, Takahashi M, Kushida K, Inoue T (1998) The preventive and interventional effects of raloxifene analog (LY117018 HCl) on osteopenia in ovariectomized rats. J Bone Miner Res 13:1005-1010
41. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
42. Ma YL, Bryant HU, Zeng Q, Palkowitz A, Jee W S S, Turner CH, et al. (2002) Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 17:2256-2264
43. Maenpaa JU, Ala-Fossi SL (1997) Toremifene in postmenopausal breast cancer: efficacy, safety and cost. Drugs Aging 11:261-270
44. Manson JE, Martin KA (2001) Postmenopausal hormone-replacement therapy. N Engl J Med 345:34-40
45. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. (2004) Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761
46. Marttunen MB, Hietanen P, Titinen A, Roth H-J, Viinikka L, Ylikorkala O (1999) Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal women with breast cancer. Calcif Tissue Int 65:365-368
47. McClung M, Omizo M, Weiss S, Moffett A, Bolognese M, Civitelli R, et al. (2004a) Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. J Bone Miner Res 19 (Suppl 1): F424
48. McClung M, Portman D, Emkey R, McKenny J, Ettinger M, Somayaji V, et al. (2004b) Comparison of theextraskeletal effects of lasofoxifene and raloxifene. 19 (Suppl 1): SA423
49. Meegan MJ, Lloyd DG (2003) Advances in the science of estrogen receptor modulation. Curr Med Chem 10:181-210
50. Miller CP, Collini MD, Tran BD, Harris HA, Kharode YP, Marzolf JT, et al. (2001) Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 44:1654-1657
51. Moffett AH, Ettinger M, Bolognese M, Weiss S, Somayaji V, Brunell R, et al. (2004) Lasofoxifene, a next generation SERM, is effective in preventing loss of BMD and reducing LDL-C in postmenopausal women. J Bone Miner Res 19 (Suppl 1): F426
52. Neele SJ, Rombouts SA, Bierlaagh MA, Barkhof F, Scheltens P, Netelenbos JC (2001) Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. J Clin Endocrinol Metab 86:1422-1424
53. Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, et al. (1998) Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 139:5224-5234
54. O'Regan RM, Cisneros GM, England GM, MacGregor JI, Muenzner HD, Assikis VJ, et al. (1998) Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth. J Natl Cancer Inst 90:1552-1555
55. Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z, et al. (2000) Selective estrogen effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact ovariectomized rats. Endocrinology 141:809-820
56. Ronkin S, Clarke L, Boudes P, Constantine G (2001) TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolissm in a dose-related fashion. J Bone Miner Res 16 (Suppl): S413
57. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O (2003) Effects of ospemifene, a novel SERM, on hormones, genitl tract, climateric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10:440-447
58. Sato M, Zeng GQ, Rowley E, Turner CH (1998) LY353381 HCl: an improved benzothiophe analog with bone efficacy complementary to parathyroid hormone-(1-34). Endocrinology 139:4642-4651
59. Savolainen-Peltonen H, Luoto NM, Kangas L, Häyry P (2004) Selective estrogen receptor modulators prevent neointima formation after vascular injury. Mol Cell Endocrinol 227:9-20
60. Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008
61. Shibata J, Toko T, Saito H, Fujioka A, Sato K, Hashimoto A, et al. (2000) Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59). Cancer Chemother Pharmacol 35:133-141
62. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. (2004) Conjugated equibe estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. J Am Med Assoc 291:2947-2958
63. Singh MM (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 21:302-347
64. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442
65. Sorbera LA, Castañer J, Silvestre JS (2002) Pipendoxifene. Drugs Future 27:942-947
66. Sutherland KM, Brady H, Gayo-Fung LM, Leisten J, Lipps SG, McKie JA, et al. (2003) Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat. Calcif Tissue Int 72:710-716
67. Taras TL, Wurz GT, De Gregorio MW (2001) In vitro and in vivo effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 77:271-279
68. Toko T, Sugimoto Y, Matsuo K, Yamasaki R, Takeda S, Wierzba K, et al. (1990) TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. Eur J Cancer 26:397-404
69. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N (2002) The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 3:153-159
70. Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, et al. (2002) Baseline characteristics of participants in the raloxifene use for the heart (RUTH) trial. Am J Cardiol 90:1204-1210
71. Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, et al. (1986) A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer 57:34-39
72. Wickerham L (2002) Tamoxifen: an update on current data and where it can now be used. Breast Cancer Res Treat 75 (Suppl 1): S7-12; discussion S33-5
73. Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, et al. (1997) Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901-3911
74. Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. J Am Med Assoc 291:1701-1712
75. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits ofestrogen plus progestin inhealthy postmenopausal women. J Am Med Assoc 288:321-333
76. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, et al. (2001) Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207-1213